US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,378.02

-2.7513-0.20%

Number of Gainers:11

Number of Losers:9

Number of Flat:- -

PE:- -

High:1,384.81

Open:1,380.53

Low:1,368.99

Close:1,380.77

Loading ...

Corvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Inc - All Cohorts Show Statistically Significant Difference From Placebo at Day 28

THOMSON REUTERS

Corvus Pharmaceuticals Announces Full Data From Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

THOMSON REUTERS

Corvus Pharmaceuticals Inc - Cohort 3 Shows Earlier and Deeper Responses Compared to Cohorts 1-2

THOMSON REUTERS

Corvus Pharmaceuticals Inc - Cohort 3 Shows Clinically Meaningful Reduction in Itch by Day 8

THOMSON REUTERS

NanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387

EXCLUSIVE-CDC official resigns from COVID vaccine committee advisory role, sources say

Kennedy: Moderna Has Agreed to a True Placebo-Controlled Trial of the New Vaccine

THOMSON REUTERS

Kennedy: FDA Will Monitor and Collect Data Throughout the Trial for Every Adverse Outcome

THOMSON REUTERS

AstraZeneca (LSE:AZN) Reports Positive Trial Results For ENHERTU® In Breast Cancer Treatment

Simply Wall St.

Johnson & Johnson announces data from two Darzalex Faspro studies

Johnson & Johnson Announces Promising Long-Term Results for CARVYKTI® in Treating Relapsed or Refractory Multiple Myeloma, Highlighting Potential for Lasting Remissions

Early Results From Johnson & Johnson's Trispecific Antibody Show Promising Response in Heavily Pretreated Multiple Myeloma Patients

THOMSON REUTERS

U.S.-Listed Shares of BioNTech up 7.5% After 18% Advance in Previous Session, Brokerages Raise PT

THOMSON REUTERS

Johnson & Johnson - 50% Reduction in Disease Progression in Brca-Altered Mcspc

THOMSON REUTERS

Johnson & Johnson - Phase 3 Amplitude Study Meets Primary Endpoint of Rpfs

THOMSON REUTERS

Johnson & Johnson Leads With First Parp Inhibitor Combo to Improve Efficacy in Patients With Hrr-Altered Mcspc

THOMSON REUTERS

How Moderna Went From Pandemic Hero to Vaccine Victim -- WSJ

U.S.-Listed Shares of BioNTech up 10% Premarket After 18% Advance in Previous Session, Brokerages Raise PT

THOMSON REUTERS

Moderna caught up in government changes to vaccine rules, WSJ says

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4568/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1378.0182,"timestamp":1748980799999,"preClose":1380.7695,"halted":0,"volume":98152081,"delay":0,"changeRate":-0.001993,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-2.751343,"latestTime":"06-03 16:00:00 EDT","open":1380.5256,"high":1384.8132,"low":1368.9906,"amount":5164854494.843995,"amplitude":0.011459,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749043800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.667477,"peRate":21.794301,"turnoverRate":0.006321,"increases":11,"decrements":9,"flats":0,"marketCap":1137146808946,"floatMarketCap":1115632112898.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1384.8132,"amplitude":0.011459,"preClose":1380.7695,"low":1368.9906,"pbRate":"3.667477","latestPrice":1378.0182,"volume":98152081,"delay":0,"open":1380.5256,"prevYearClose":1274.8187,"prevWeekClose":1383.2164,"prevMonthClose":1383.2164,"prevQuarterClose":1427.887,"fiveDayClose":1370.7961,"twentyDayClose":1366.6433,"sixtyDayClose":1480.0557,"secType":"PLATE","market":"US","turnoverRate":0.006321,"peRate":21.794301,"marketCap":1137146808946,"floatMarketCap":1115632112898.5,"timestamp":1748980799999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":11,"down":9,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540467050","title":"Corvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2540467050","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540467050?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:01","pubTimestamp":1749034868,"startTime":"0","endTime":"0","summary":"Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has announced new interim data from its Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis. The trial is randomized, double-blind, and placebo-controlled, focusing on 48 patients across three cohorts. Cohort 3, receiving 200 mg twice daily, showed earlier and deeper responses compared to cohorts 1 and 2. At day 28, cohort 3 demonstrated a 64.8% mean reduction in the Eczema Area and Severity Index  score, compared to 54.6% for cohorts 1 and 2 combined, and 34.4% for the placebo group. The company has also initiated an extension cohort study exploring the cohort 3 dose over an 8-week period. Dr. Miller is set to present the findings at the Jefferies Global Healthcare Conference on June 5, 2025, with the presentation available via webcast on the Corvus website.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL4wNLXy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","CRVS"],"gpt_icon":0},{"id":"2540905010","title":"Corvus Pharmaceuticals Inc - All Cohorts Show Statistically Significant Difference From Placebo at Day 28","url":"https://stock-news.laohu8.com/highlight/detail?id=2540905010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540905010?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:00","pubTimestamp":1749034801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nTUA1Y3VCT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVS","BK4139","BK4568"],"gpt_icon":0},{"id":"2540705055","title":"Corvus Pharmaceuticals Announces Full Data From Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2540705055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540705055?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:00","pubTimestamp":1749034801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nTUA1Y3VCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","CRVS","BK4139"],"gpt_icon":0},{"id":"2540501770","title":"Corvus Pharmaceuticals Inc - Cohort 3 Shows Earlier and Deeper Responses Compared to Cohorts 1-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2540501770","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540501770?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:00","pubTimestamp":1749034801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nTUA1Y3VCT:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVS","BK4568","BK4139"],"gpt_icon":0},{"id":"2540050489","title":"Corvus Pharmaceuticals Inc - Cohort 3 Shows Clinically Meaningful Reduction in Itch by Day 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2540050489","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540050489?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:00","pubTimestamp":1749034801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nTUA1Y3VCT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVS","BK4568"],"gpt_icon":0},{"id":"2540050346","title":"NanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387","url":"https://stock-news.laohu8.com/highlight/detail?id=2540050346","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540050346?lang=en_us&edition=fundamental","pubTime":"2025-06-04 18:55","pubTimestamp":1749034520,"startTime":"0","endTime":"0","summary":"NanoViricides Inc., a clinical-stage company specializing in broad-spectrum antivirals, has announced the imminent commencement of an animal study for its Measles drug development program. The study will evaluate drug candidates in a lethal animal infection model, using specially modified mice that express the human CD150/SLAM protein, necessary for Measles virus entry into cells. The company is advancing its drug NV-387, which previously demonstrated efficacy against RSV in animals and may show similar effectiveness against Measles. NV-387 acts by mimicking cell features to bind and destroy viruses. The study aims to assess NV-387's potential for treating Measles, addressing a growing need as current Measles genotypes drift from existing vaccine strains. There is currently no approved drug for Measles, with Vitamin A and ribavirin being used in specific cases. Results from this study will inform the potential human application of NV-387.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL47VQjN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","NNVC","BK4139"],"gpt_icon":0},{"id":"2540003227","title":"EXCLUSIVE-CDC official resigns from COVID vaccine committee advisory role, sources say","url":"https://stock-news.laohu8.com/highlight/detail?id=2540003227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540003227?lang=en_us&edition=fundamental","pubTime":"2025-06-04 05:53","pubTimestamp":1748987633,"startTime":"0","endTime":"0","summary":"EXCLUSIVE-CDC official resigns from COVID vaccine committee advisory role, sources sayOfficial who resigned co-led work group on COVID-19 vaccine useMove follows RFK Jr.'s changes to vaccine immunization schedule without CDC advisers' inputVaccine advisory panel meeting set for June 25-27Adds details about CDC advisory group discussions, upcoming meeting in paragraphs 12-15By Julie Steenhuysen, Michael Erman and Dan Levine","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nL2N3S60ZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4501","BK4532","BK4533","BK4534","BK4588","BK4585","BK4568","BK4139","BK4551"],"gpt_icon":1},{"id":"2540707285","title":"Kennedy: Moderna Has Agreed to a True Placebo-Controlled Trial of the New Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2540707285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540707285?lang=en_us&edition=fundamental","pubTime":"2025-06-04 05:26","pubTimestamp":1748985965,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nS0N3RM03D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4548","BK4568","MRNA","BK4139","BK4585","BK4533","BK4501","BK4551","BK4532","BK4588"],"gpt_icon":0},{"id":"2540707283","title":"Kennedy: FDA Will Monitor and Collect Data Throughout the Trial for Every Adverse Outcome","url":"https://stock-news.laohu8.com/highlight/detail?id=2540707283","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540707283?lang=en_us&edition=fundamental","pubTime":"2025-06-04 05:26","pubTimestamp":1748985965,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nS0N3RM03D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4585","BK4533","BK4501","BK4532","BK4551","MRNA","BK4568","BK4548","BK4139","BK4588"],"gpt_icon":0},{"id":"2540702479","title":"AstraZeneca (LSE:AZN) Reports Positive Trial Results For ENHERTU® In Breast Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540702479","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540702479?lang=en_us&edition=fundamental","pubTime":"2025-06-04 01:45","pubTimestamp":1748972740,"startTime":"0","endTime":"0","summary":"AstraZeneca recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing commitment to enhancing therapeutic options for HER2-positive metastatic breast cancer. Over the last week, AstraZeneca's share price increased by 1%, aligning closely with the broader market's growth of 2%. While the company's recent product developments, including trials for ENHERTU and IMFINZI, and collaborations like the partnership with Danaher Corporation, underscore its innovation in oncology, these advancements likely added some weight to the overall market trend rather than significantly influencing the stock's performance in isolation.We've discovered 3 weaknesses for AstraZeneca that you should be aware of before investing here.LSE:AZN Revenue & Expenses Breakdown as at Jun 2025. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-lse-azn-reports-positive-174540352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765992.SGD","BK4007","LU0109394709.USD","LU2236285917.USD","BK4585","BK4588","LU2462157665.USD","AZN","LU2417539215.USD","LU2456880835.USD","BK4568","LU1829250122.USD","BK4179","LU0889565916.HKD","LSE"],"gpt_icon":0},{"id":"2540559708","title":"Johnson & Johnson announces data from two Darzalex Faspro studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2540559708","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540559708?lang=en_us&edition=fundamental","pubTime":"2025-06-03 22:55","pubTimestamp":1748962523,"startTime":"0","endTime":"0","summary":"Johnson & Johnson announced data from two studies highlighting that a Darzalex Faspro based quadruplet regimen demonstrated deep and sustained mini...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/johnson-johnson-announces-data-from-two-darzalex-faspro-studies-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/johnson-johnson-announces-data-from-two-darzalex-faspro-studies-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1244550221.USD","LU0912757837.SGD","LU1894683348.USD","LU1267930813.SGD","LU0795875169.SGD","LU1244550577.SGD","LU1221951129.SGD","LU1261432733.SGD","LU1674673428.USD","LU1732800096.USD","IE00BDGV0183.EUR","LU0889566641.SGD","LU1196500208.SGD","BK4504","LU1066053197.SGD","IE0009355771.USD","LU0058720904.USD","LU0795875086.SGD","LU1162221912.USD","BK4585","LU1074936037.SGD","BK4568","LU1221951046.USD","LU1244550494.USD","LU0234572021.USD","BK4550","LU0345770308.USD","LU0640476718.USD","LU0234570918.USD","LU1732799900.SGD","LU0345769631.USD","BK4533","LU1280957306.USD","LU0203347892.USD","IE00BFXG1179.USD","JNJ","IE00B3PB1722.GBP","LU0466842654.USD","LU2133065610.SGD","LU1059921491.USD","IE000M9KFDE8.USD","BK4532","LU2505996509.AUD","BK4588","LU1718418525.SGD","LU2129689514.USD","LU2112291526.USD","LU2430703251.USD","BK4534","BK4007"],"gpt_icon":0},{"id":"2540702687","title":"Johnson & Johnson Announces Promising Long-Term Results for CARVYKTI® in Treating Relapsed or Refractory Multiple Myeloma, Highlighting Potential for Lasting Remissions","url":"https://stock-news.laohu8.com/highlight/detail?id=2540702687","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540702687?lang=en_us&edition=fundamental","pubTime":"2025-06-03 22:45","pubTimestamp":1748961938,"startTime":"0","endTime":"0","summary":"Johnson & Johnson Announces Promising Long-Term Results for CARVYKTI in Treating Relapsed or Refractory Multiple Myeloma, Highlighting Potential for Lasting Remissions. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire  on June 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL4Xp2WY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2112291526.USD","LU2430703251.USD","LU0203347892.USD","IE00B42XCP33.USD","LU2129689605.HKD","LU2133065610.SGD","LU0203345920.USD","LU1061106388.HKD","LU1778281490.HKD","LU0466842654.USD","LU1066053197.SGD","LU1267930813.SGD","LU2602419157.SGD","LU0795875169.SGD","LU1894683264.USD","LU0792757196.USD","LU0345769128.USD","LU1674673428.USD","SG9999001440.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","BK4532","LU0234572021.USD","LU1732799900.SGD","LU1221951129.SGD","LU0345769631.USD","BK4534","IE0002141913.USD","IE00B19Z3B42.SGD","LU1059921491.USD","LU1221951046.USD","LU0889566641.SGD","IE0002270589.USD","IE00B3PB1722.GBP","LU1261432733.SGD","LU1718418525.SGD","LU1506573853.SGD","IE00BBT3K403.USD","IE00BVYPNV92.GBP","BK4588","LU0985320562.USD","IE00BGHQF631.EUR","JNJ","BK4581","IE00BJT1NW94.SGD","BK4585","LU0882574055.USD","BK4568","IE00B1BXHZ80.USD","SG9999002224.SGD"],"gpt_icon":0},{"id":"2540256770","title":"Early Results From Johnson & Johnson's Trispecific Antibody Show Promising Response in Heavily Pretreated Multiple Myeloma Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2540256770","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540256770?lang=en_us&edition=fundamental","pubTime":"2025-06-03 22:45","pubTimestamp":1748961902,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUABCQZZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","IE00BFTCPJ56.SGD","LU0234572021.USD","IE0002270589.USD","LU0795875169.SGD","BK4568","IE0002141913.USD","SG9999001440.SGD","LU0345769128.USD","IE00BJT1NW94.SGD","LU0985320562.USD","BK4585","LU1506573853.SGD","LU1718418525.SGD","LU1778281490.HKD","LU1066053197.SGD","LU0345769631.USD","IE00B1BXHZ80.USD","LU2133065610.SGD","LU0466842654.USD","LU0203345920.USD","LU2129689605.HKD","BK4588","IE0009355771.USD","LU1221951046.USD","LU1221951129.SGD","LU0203347892.USD","BK4532","IE00BGHQF631.EUR","IE00B19Z3B42.SGD","LU1894683264.USD","IE00B42XCP33.USD","LU0882574055.USD","IE00BVYPNV92.GBP","LU1059921491.USD","JNJ","LU2602419157.SGD","IE00B3PB1722.GBP","LU0792757196.USD","LU1732799900.SGD","BK4581","LU1061106388.HKD","LU1261432733.SGD","LU1674673428.USD","SG9999002224.SGD","LU1267930813.SGD","LU2430703251.USD","LU0889566641.SGD","LU2112291526.USD","IE00BBT3K403.USD"],"gpt_icon":0},{"id":"2540977265","title":"U.S.-Listed Shares of BioNTech up 7.5% After 18% Advance in Previous Session, Brokerages Raise PT","url":"https://stock-news.laohu8.com/highlight/detail?id=2540977265","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540977265?lang=en_us&edition=fundamental","pubTime":"2025-06-03 21:32","pubTimestamp":1748957549,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nL3N3S611Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BNTX","BK4551","BK4535","BK4585","BK4568","BK4588","BK4548","BK4139"],"gpt_icon":0},{"id":"2540796217","title":"Johnson & Johnson - 50% Reduction in Disease Progression in Brca-Altered Mcspc","url":"https://stock-news.laohu8.com/highlight/detail?id=2540796217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540796217?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:00","pubTimestamp":1748952020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S5101:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1244550221.USD","IE00BFTCPJ56.SGD","LU1244550577.SGD","LU2430703178.SGD","LU0889566641.SGD","IE00BSNM7G36.USD","LU1066051225.USD","LU2129689514.USD","LU2129689605.HKD","LU2505996509.AUD","IE00B3PB1722.GBP","IE00B19Z3B42.SGD","LU1196500208.SGD","LU2112291526.USD","BK4585","LU0795875086.SGD","SG9999001440.SGD","BK4592","LU1244550494.USD","LU1261432733.SGD","LU0345770993.USD","LU1059921491.USD","BK4568","LU0795875169.SGD","LU0203345920.USD","BK4588","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU1674673691.USD","IE0002141913.USD","IE00BFXG1179.USD","IE00B42XCP33.USD","LU0345769631.USD","LU1894683348.USD","IE00BDGV0183.EUR","BK4559","JNJ","LU0234572021.USD","IE0009355771.USD","LU2347655156.SGD","IE0002270589.USD","LU1267930813.SGD","LU0985320562.USD","IE00B1BXHZ80.USD","LU0912757837.SGD","LU1280957306.USD","LU2602419157.SGD","LU2133065610.SGD","IE00BN8TJ469.HKD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2540796067","title":"Johnson & Johnson - Phase 3 Amplitude Study Meets Primary Endpoint of Rpfs","url":"https://stock-news.laohu8.com/highlight/detail?id=2540796067","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540796067?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:00","pubTimestamp":1748952020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S5101:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","IE00B3T34201.USD","LU2129689605.HKD","SG9999001440.SGD","IE0002270589.USD","IE00B7SZLL34.SGD","LU0912757837.SGD","IE00BN8TJ469.HKD","LU1280957306.USD","IE00B3PB1722.GBP","LU2347655156.SGD","JNJ","LU0795875169.SGD","IE0002141913.USD","LU0345769631.USD","LU0889566641.SGD","LU0345770993.USD","LU1066051225.USD","LU1244550577.SGD","LU2505996509.AUD","BK4592","IE0009355771.USD","IE00BFXG1179.USD","BK4585","LU2430703178.SGD","LU1674673691.USD","LU1244550221.USD","LU2112291526.USD","LU1267930813.SGD","LU0203345920.USD","LU1261432733.SGD","BK4588","BK4559","IE00B42XCP33.USD","IE00BSNM7G36.USD","LU2602419157.SGD","LU1196500208.SGD","LU1894683348.USD","LU0795875086.SGD","IE00B1BXHZ80.USD","LU2133065610.SGD","IE00BFTCPJ56.SGD","LU0234572021.USD","LU2129689514.USD","IE00B19Z3B42.SGD","IE00BDGV0183.EUR","LU1244550494.USD","LU1059921491.USD","IE00BLSP4452.SGD","LU0985320562.USD"],"gpt_icon":0},{"id":"2540779989","title":"Johnson & Johnson Leads With First Parp Inhibitor Combo to Improve Efficacy in Patients With Hrr-Altered Mcspc","url":"https://stock-news.laohu8.com/highlight/detail?id=2540779989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540779989?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:00","pubTimestamp":1748952020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S5101:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1244550577.SGD","JNJ","IE00BDGV0183.EUR","LU0795875169.SGD","LU2602419157.SGD","IE00BSNM7G36.USD","BK4592","IE00B19Z3B42.SGD","IE00B3T34201.USD","SG9999001440.SGD","BK4568","LU1894683348.USD","IE00BLSP4452.SGD","LU2112291526.USD","IE0002141913.USD","LU2430703178.SGD","LU1674673691.USD","LU1267930813.SGD","IE0002270589.USD","LU0345770993.USD","IE00B3PB1722.GBP","BK4588","LU1244550494.USD","LU2129689605.HKD","LU0203345920.USD","LU0912757837.SGD","LU0345769631.USD","IE00B42XCP33.USD","LU2129689514.USD","IE00B1BXHZ80.USD","LU2505996509.AUD","IE00BN8TJ469.HKD","LU1066051225.USD","LU1261432733.SGD","LU2133065610.SGD","IE00BFXG1179.USD","IE00B7SZLL34.SGD","IE0009355771.USD","LU2347655156.SGD","LU1244550221.USD","LU1059921491.USD","BK4585","LU1280957306.USD","BK4559","IE00BFTCPJ56.SGD","LU0985320562.USD","LU0889566641.SGD","LU0234572021.USD","LU1196500208.SGD","LU0795875086.SGD"],"gpt_icon":0},{"id":"2540166779","title":"How Moderna Went From Pandemic Hero to Vaccine Victim -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2540166779","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540166779?lang=en_us&edition=fundamental","pubTime":"2025-06-03 19:59","pubTimestamp":1748951940,"startTime":"0","endTime":"0","summary":"Moderna was once a darling of the first Trump administration, which went to great lengths to help the company develop its Covid-19 vaccine that protected millions of people from the virus. Now the biotech is caught in the crossfire of Trump 2.0 as vaccine-making comes under fire.In the latest setback for Moderna, the Food and Drug Administration on Friday approved its next-generation Covid shot for a narrower population of patients than the company intended. The approval grants use of the vaccine only in older adults and people aged 12 to 64 with health risks.HHS Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic, said recently that certain shots for respiratory diseases including mRNA vaccines have \"never worked.\" In mid-May, Kennedy said the Centers for Disease Control and Prevention would no longer recommend that pregnant women and children get Covid-19 vaccines as a matter of routine. The industry is also navigating an FDA that has shed thousands of workers.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","BK4599","BK4532","BK4592","LU0225284248.USD","LU1829250122.USD","IE00BLSP4452.SGD","GSK","LU0234572021.USD","PFE","SG9999001176.USD","LU1883839398.USD","LU0058720904.USD","LU0289739699.SGD","SG9999011175.SGD","LU1066051498.USD","SG9999002224.SGD","BK4585","BK4139","LU0122379950.USD","IE000M9KFDE8.USD","BK4551","LU0306806265.USD","BK4581","LU0985481810.HKD","MRNA","LU0456855351.SGD","LU1057294990.SGD","SG9999002232.USD","SGXZ57979304.SGD","BK4534","BK4588","SG9999001176.SGD","LU0225771236.USD","IE0002270589.USD","LU0321505439.SGD","LU0170899867.USD","BK4568","IE00BLSP4239.USD","BK4550","SG9999003800.SGD","GSK.UK","IE00B19Z3B42.SGD","BK4007","BK4501","IE00BBT3K403.USD","LU1066053197.SGD","LU1894683348.USD","LU0868494617.USD","BK4548"],"gpt_icon":0},{"id":"2540177573","title":"U.S.-Listed Shares of BioNTech up 10% Premarket After 18% Advance in Previous Session, Brokerages Raise PT","url":"https://stock-news.laohu8.com/highlight/detail?id=2540177573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540177573?lang=en_us&edition=fundamental","pubTime":"2025-06-03 19:13","pubTimestamp":1748949222,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nL3N3S60UC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4551","BK4548","BK4568","BNTX","BK4535","BK4585","BK4588"],"gpt_icon":0},{"id":"2540778146","title":"Moderna caught up in government changes to vaccine rules, WSJ says","url":"https://stock-news.laohu8.com/highlight/detail?id=2540778146","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540778146?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:10","pubTimestamp":1748945451,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) is in a precarious position, the company bet big on mRNA to develop shots to treat or prevent different diseases, but, after securin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderna-caught-up-in-government-changes-to-vaccine-rules-wsj-says-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderna-caught-up-in-government-changes-to-vaccine-rules-wsj-says-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4139","BK4551","BK4588","MRNA","BK4585","BK4534","BK4532","BK4568","BK4501","BK4533"],"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":1,"totalSize":213,"code":"91000000","status":"200"}]}}